R
Robert A. Redd
Researcher at Harvard University
Publications - 54
Citations - 984
Robert A. Redd is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Diffuse large B-cell lymphoma. The author has an hindex of 13, co-authored 54 publications receiving 454 citations.
Papers
More filters
Journal ArticleDOI
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu,Donna E. Leet,Rosa Lundbye Allesøe,Giacomo Oliveira,Shuqiang Li,Shuqiang Li,Adrienne M. Luoma,Jinyan Liu,Juliet Forman,Juliet Forman,Teddy Huang,J. Bryan Iorgulescu,J. Bryan Iorgulescu,Rebecca L. Holden,Siranush Sarkizova,Satyen H. Gohil,Satyen H. Gohil,Satyen H. Gohil,Robert A. Redd,Jing Sun,Liudmila Elagina,Anita Giobbie-Hurder,Wandi Zhang,Lauren Peter,Zoe B. Ciantra,Scott J. Rodig,Scott J. Rodig,Oriol Olive,Keerthi Shetty,Jason Pyrdol,Mohamed Uduman,Patrick C. Lee,Pavan Bachireddy,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Charles H. Yoon,Donna Neuberg,Bradley L. Pentelute,Bradley L. Pentelute,Nir Hacohen,Nir Hacohen,Kenneth J. Livak,Sachet A. Shukla,Sachet A. Shukla,Lars Rønn Olsen,Lars Rønn Olsen,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Kai W. Wucherpfennig,Edward F. Fritsch,Edward F. Fritsch,Derin B. Keskin,Derin B. Keskin,Catherine J. Wu,Patrick A. Ott +56 more
TL;DR: In this paper, the authors evaluated the long-term effects of personal neoantigen vaccines and found that they can induce durable and specific memory T cell clones that have cytotoxic gene signatures and can diversify to include non-vaccine specificities.
Journal ArticleDOI
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Tarek H. Mouhieddine,Tarek H. Mouhieddine,Adam S. Sperling,Robert A. Redd,Jihye Park,Jihye Park,Matthew Leventhal,Christopher J. Gibson,Salomon Manier,Salomon Manier,Salomon Manier,Amin Nassar,Amin Nassar,Marzia Capelletti,Daisy Huynh,Mark Bustoros,Mark Bustoros,Romanos Sklavenitis-Pistofidis,Romanos Sklavenitis-Pistofidis,Sabrin Tahri,Sabrin Tahri,Kalvis Hornburg,Henry Dumke,Muhieddine M. Itani,Cody J. Boehner,Chia Jen Liu,Saud H. AlDubayan,Brendan Reardon,Eliezer M. Van Allen,Jonathan J Keats,Chip Stewart,Shaadi Mehr,Daniel Auclair,Robert L. Schlossman,Nikhil C. Munshi,Kenneth C. Anderson,David P. Steensma,Jacob P. Laubach,Paul G. Richardson,Jerome Ritz,Benjamin L. Ebert,Benjamin L. Ebert,Robert J. Soiffer,Lorenzo Trippa,Gad Getz,Gad Getz,Donna Neuberg,Irene M. Ghobrial,Irene M. Ghobrial +48 more
TL;DR: The authors show that the presence of clonal haematopoiesis of indeterminate potential (CHIP) at time of ASCT is associated with adverse outcomes in MM patients.
Journal ArticleDOI
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
Fathima Zumla Cader,Fathima Zumla Cader,Xihao Hu,Walter Goh,Kirsty Wienand,Jing Ouyang,Elisa Mandato,Robert A. Redd,Lee N. Lawton,Pei-Hsuan Chen,Jason L. Weirather,Ron C. J. Schackmann,Bo Li,Bo Li,Wenjiang Ma,Philippe Armand,Scott J. Rodig,Donna Neuberg,X. Shirley Liu,Margaret A. Shipp +19 more
TL;DR: In a phase II clinical trial of patients with classical Hodgkin lymphoma, peripheral CD4+ T cell receptor diversity and the abundance of mature natural killer cells and CD3−CD68+CD4+GrB+ innate cells were associated with favorable responses to anti-PD-1 monotherapy.
Journal ArticleDOI
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
Bjoern Chapuy,Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Kirsty Wienand,Atanas Kamburov,Gabriel K. Griffin,Pei-Hsuan Chen,Ana Lako,Robert A. Redd,Claire McEwen Cote,Matthew D. Ducar,Aaron R. Thorner,Scott J. Rodig,Gad Getz,Gad Getz,Margaret A. Shipp +17 more
TL;DR: A comprehensive analysis of recurrent genetic alterations - somatic mutations, somatic copy number alterations (SCNAs) and structural variants - in a cohort of 37 newly diagnosed primary mediastinal large B-cell lymphomas finds several previously uncharacterized molecular features that may increase sensitivity to PD-1 blockade.
Journal ArticleDOI
Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma.
Sarju Ganatra,Sarju Ganatra,Sarju Ganatra,Robert A. Redd,Salim S. Hayek,Rohan Parikh,Tariq U. Azam,Gregory A. Yanik,Lauren Spendley,Sarah Nikiforow,Caron A. Jacobson,Anju Nohria,Anju Nohria +12 more
TL;DR: In this paper, the authors propose a method to solve the problem of "missing links".http://www.theguardian.com/blogs/blogs-and-blogs.